CD274 and renal cell carcinoma: Anti-programmed cell death protein-1 (PD-1) and programmed cell death protein ligand-1 (PD-L1) agents have remarkably changed the therapeutic strategies in many cancers, such as melanoma, lung cancer, renal cell carcinoma, head and neck cancer and so on.